SeaStar Medical Holding Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ICU | BCDA | SNGX | JSPR | REVB | CYP.AX | |
|---|---|---|---|---|---|---|
| Market cap | 10.84M | 13.82M | 7.64M | 17.01M | 2.34M | 4.38M |
| P/E (TTM) | — | — | — | — | 0.1 | — |
| Forward P/E | -0.8 | -1.6 | -1.4 | -0.7 | -0.2 | -0.2 |
| Price/book | 2.0 | 5.1 | 1.1 | 10.2 | 0.2 | -6.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −60.47% | −28.91% | −73.91% | −75.38% | −85.35% | −94.47% |
| Today | +2.00% | −0.92% | −1.49% | +6.48% | −7.05% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All ICU news ›SeaStar Medical Meets FDA Post-Approval Study Requirements for QUELIMMUNE
TradingView SeaStar Medical Meets FDA Post-Approval Study Requirements for QUELIMMUNE SeaStar Medical said the FDA confirmed QUELIMMUNE’s pediatric SAVE Registry fulfilled the therapy’s post-approval study requirements, enabl
SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award
Award recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support Keynote presentation and award ceremony to occur at…
SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI
New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital discharge versus…
Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
(Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the publication of results from a multicenter study titled ... Nuwellis Announces Acceptance of…
Analyzing Orthofix Medical (NASDAQ:OFIX) and SeaStar Medical (NASDAQ:ICU)
Posted by Danessa Lincoln on Oct 23rd, 2026 Orthofix Medical (NASDAQ:OFIX – Get Free Report) and SeaStar Medical (NASDAQ:ICU – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare…
SeaStar Medical raises about $3.3M from warrants
Asia Broadband Board Approves Additional $18 Million for Stock Repurchases, Bringing Authorized Total Repurchases Up to $30 Million Forgent Announces CFO Transition BrainChip Unveils AKD1500 SPI Chip, Bringing Neuromorphic AI to Everyday…
FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition
October 07, 2026 08:16 ET | Source: SeaStar Medical SeaStar Medical Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net4
- manilatimes.net2
- markets.businessinsider.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.